Reata Pharmaceuticals Inc. (RETA) said that its stockholders have approved the company's previously announced acquisition by Biogen Inc. (BIIB).Reata said that about 99.65 percent of the votes cast by the Company's Class A common stockholders and Class B common stockholders voted to approve the Merger, which represents approximately 87.99 percent of the total voting power of the shares of the Company's Class A common stock and Class B common stock entitled to vote at the special meeting.

Reata Pharmaceuticals Inc.（RETA）表示，其股东已批准该公司之前宣布的Biogen Inc.（BIIB）收购.Reata表示，该公司A类普通股东和B类普通股东投票批准的投票约占99.65%，占本公司A类普通股和B类普通股有权在特别会议上投票的股份总表决权的约87.99%。

The companies expect to close the merger on September 26, 2023..

公司预计将于2023年9月26日结束合并。。

In July, Biogen agreed to acquire Reata Pharmaceuticals for $172.50 per share in cash, reflecting an enterprise value of around $7.3 billion. For comments and feedback contact: editorial@rttnews.comBusiness News

7月，Biogen同意以每笔现金172.50美元的价格收购Reata Pharmaceuticals，反映企业价值约73亿美元。有关意见和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision in August 2023

2023年8月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In June 2023

2023年6月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In April 2023

2023年4月面临FDA决定的生物技术股票